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Abstract: Tuberculosis (TB) is the leading cause of death among HIV-1-infected individuals and
Mycobacterium tuberculosis (Mtb) co-infection is an early precipitate to AIDS. We aimed to determine
whether Mtb strains differentially modulate cellular susceptibility to HIV-1 infection (cis- and trans-
infection), via surface receptor interaction by their cell envelope lipids. Total lipids from pathogenic
(lineage 4 Mtb H37Rv, CDC1551 and lineage 2 Mtb HN878, EU127) and non-pathogenic (Mycobac-
terium bovis BCG and Mycobacterium smegmatis) Mycobacterium strains were integrated into liposomes
mimicking the lipid distribution and antigen accessibility of the mycobacterial cell wall. The resulting
liposomes were tested for modulating in vitro HIV-1 cis- and trans-infection of TZM-bl cells using
single-cycle infectious virus particles. Mtb glycolipids did not affect HIV-1 direct infection however,
trans-infection of both R5 and X4 tropic HIV-1 strains were impaired in the presence of glycolipids
from M. bovis, Mtb H37Rv and Mtb EU127 strains when using Raji-DC-SIGN cells or immature and
mature dendritic cells (DCs) to capture virus. SL1, PDIM and TDM lipids were identified to be
involved in DC-SIGN recognition and impairment of HIV-1 trans-infection. These findings indicate
that variant strains of Mtb have differential effect on HIV-1 trans-infection with the potential to
influence HIV-1 disease course in co-infected individuals.
Keywords: HIV-1; TB; Mycobacterium tuberculosis; in vitro; DC-SIGN; liposomes; trans-infection; SL1;
TDM; PDIM; H37Rv; HN878; CDC1551; EU127; BCG; M. smegmatis
1. Introduction
Human immunodeficiency virus type 1 (HIV-1) and Mycobacterium tuberculosis (Mtb)
co-infection results in a loss of numerous immunological functions and ultimately leads
to death when not treated. The WHO estimated in 2019 that 208,000 people died of HIV-
associated tuberculosis [1]. Both, Mtb and HIV-1 can induce profound changes in the host
immune response resulting in increased rates of active Mtb disease or the exacerbation
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of HIV-1 infection. Mtb creates a favorable environment for HIV-1 direct infection (cis-
infection) and/or replication, as Mtb infection leads to the activation and induction of
immune responses [2–4].
Due to the glycosylation of the mycobacterial cell wall and HIV-1 envelope protein
gp120, both pathogens engage C-type lectin receptors [5]. In the case of HIV-1, numerous
cells of the immune system, including dendritic cells, can bind and capture HIV-1 via an
array of C-type lectins expressed on the cell surface. Binding not only promotes the capture,
processing and subsequent presentation of HIV-1 antigen to other cells of the immune
system but can result in the capture and transfer of HIV-1 virions to susceptible cells, a
mechanism termed trans-infection [6–9]. Different receptors have been described to be
involved with trans-infection, such as the mannose receptor MR [6,10,11] and the C-type
lectin receptor DC-SIGN [12–15], alongside Siglec via interactions with ganglioside GM3
localised on the virus membrane [16–20].
The mycobacterial cell envelope is complex and composed of carbohydrate polymers
such as arabinogalactan (AG) and distinct lipids including mycolic acids (MA) linked
to peptidoglycans (PG) and free lipids trehalose dimycolate (TDM), phthiocerol dimy-
cocerosate (PDIM/DIM), sulfolipids (SLs), phosphatidylinositol mannosides (PIM), lipo-
mannan (LM) and lipoarabinomannan (LAM) [21–26]. These outer envelope lipids play
an important role in structural integrity and can modulate the host immune response,
therefore influencing Mycobacterium pathogenicity. MA constitutes a natural barrier of the
bacteria and the nature of its composition and oxygenation can influence Mtb pathogenic-
ity [27,28] by modulation of macrophage activation and differentiation [29,30]. In addition,
the inflammatory response can be associated with AG and PG structures [31]. TDM (also
known as cord factor) is a major contributor to inflammation [32–35] and can also modulate
macrophage activation [32,36,37], macrophage surface markers expression [38] and granu-
loma formation [39,40]. SLs are sulphated trehalose esters and several studies using Mtb
mutants in SL1 biosynthesis have revealed its role in Mtb virulence, for example, mmpL8
knock-out mutants of Mtb have been shown to attenuate bacterial virulence in mouse
models [41,42]. PDIMs have been described to play a role in Mtb virulence [43,44] and
the presence of PDIMs at the bacterial surface can aide escape from macrophage recog-
nition [45,46], mask pathogen associated molecular patterns (PAMPs) [47], and prevent
macrophage recruitment [48]. PIMs are glycoconjugates and represent the major compo-
nents of the mycobacterial cell envelope and are precursors of LM, LAM and mannan
capped lipoarabinomannan (ManLAM). Mannoside caps associated to PIMs can be recog-
nised by phagocytic receptors such as C-type lectins, including MR and DC-SIGN [49–51].
Additionally, LM has been described as a TLR2 and TLR4 ligand, modulating anti- and
pro-inflammatory responses against the bacteria [52–56].
The proportion of lipids present within the mycobacterial cell wall can vary between
Mycobacterium strains resulting in different biochemical properties [57,58]. Variation in
lipid compositions inside Mtb species can impact on their pathogenicity. Different clinical
Mtb strains are associated with important disparities in immune response activation such
as CDC1551 and HN878 [59–62]. Compared to the lineage 4 CDC1551, the lineage 2 Beijing
strain HN878 induces an altered immune response partly due to its expression of phenolic
glycolipids (PGL), increasing its virulence [63–66]. In order to measure and compare the
impact of glycolipids derived from different Mycobacterium strains on HIV-1 cis- and trans-
infection, we developed liposomes which contained Mycobacterium total lipid extracts
from lineage 4 Mtb H37Rv, and CDC1551, lineage 2 Mtb HN878 and non-pathogenic M.
bovis BCG and M. smegmatis. These liposomes are artificial vesicles composed of a mix of
phosphatidylcholine (PC) and cholesterol (Ch) and used as the experimental foundation in
our assays. In many cases, liposomes have been used as a carrier for various applications
in pharmacology, including for diagnostic purposes, therapeutic treatments of cancer and
for use in vaccine technologies [67]. In the context of TB, the interest in using liposomes for
vaccination strategies is important and well described in the literature [68–73].
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2. Results
2.1. Production of Liposomes Containing Mycobacterium Total Lipids
The initial aim was to identify whether we could incorporate lipid extract antigens
from variant Mycobacterium strains into liposomes. Unilamellar liposomes were generated
with total lipid extracts from differing strains as described. We characterised 0.8PC:0.2Ch,
M. bovis and Mtb H37Rv liposomes generated by NanoSight technology (Figure 1) and
Thin-layer chromatography TLC (Figure 2).
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 Figure 1. Liposome-size analysis by NanoSight particle tracking. (A) Liposomes generated with
the Extruder system at 100 nm size, (B) Liposomes generated with the Extruder system at 200 nm
size (C) 0.8PC:0.2Ch, (D) BCG batch n◦ 1, (E) BCG batch n◦ 2 and (F) H37Rv liposomes made by
sonication without the Extruder step. Liposome suspensions were diluted 1:1000–1:2000 in PBS,
and three 60 s videos were recorded. The data shown are from one experiment. On the right are
graphs showing the results of particle concentration and their size measurement; and on the left are
liposomes observed at the screen shot from NTA video.




Figure 1. Liposome-size analysis by NanoSight particle tracking. (A) Liposomes generated with 
the Extruder system at 100 nm size, (B) Liposomes generated with the Extruder system at 200 nm 
size (C) 0.8PC:0.2Ch, (D) BCG batch n° 1, (E) BCG batch n° 2 and (F) H37Rv liposomes made by 
sonication without the Extruder step. Liposome suspensions were diluted 1:1000–1:2000 in PBS, 
and three 60 s videos were recorded. The data shown are from one experiment. On the right are 
graphs showing the results of particle concentration and their size measurement; and on the left 
are liposomes observed at the screen shot from NTA video. 
 
Figure 2. Thin-layer chromatography (TLC) analyses of 0.8PC:0.2Ch, BCG and H37Rv liposomes. 
10 µL of liposomes solution made in water were spotted and dried on a silica gel 60 F254 plate. 
Separation occurred in 60:16:2 CHCl3:MeOH:H2O solvent and was visualised by staining with 
molybdophosphoric acid and charring. The arrows show the presence of lipids from mycobacte-
rial origin. The data are from one representative experiment. 
Visualisation of liposome particles using NanoSight NS300 optics and software was 
used to define their size and distribution (Figure 1). Calibrated liposomes were generated 
with an additional step of extrusion following sonication, producing: 0.8PC:0.2Ch lipo-
somes at 100 nm (Figure 1A) and 200 nm (Figure 1B), respectively. In parallel, 0.8PC:0.2Ch 
liposomes were produced with a step of sonication only with no calibration (Figure 1C). 
Two separate batches of M. bovis liposomes were generated (Figure 1D,E) and each meas-
ured on average 221.3 and 229 nm, respectively, while the mean size of H37Rv liposomes 
(Figure 1F) was 201.7 nm. The similar sizes and distribution of the two independent prep-
arations of M. bovis liposomes demonstrates the reproducibility of the liposome genera-
tion technique. Due to a single sonication step, the population of M. bovis and H37Rv lip-
osomes generated is heterogenous compared to calibrated liposomes at 100 nm and 200 
nm. Additionally, Mycobacterium liposomes appear larger than the calibrated liposomes 
[0.8PC:0.2Ch 100 nm (140.8 nm), 0.8PC:0.2Ch 200 nm (182.9 nm)] and 0.8PC:0.2Ch lipo-
somes generated with a single sonication step (171.4 nm, Figure 1C). This size variation is 
likely explained by the incorporation of the Mycobacterium lipids onto M. bovis and H37Rv 
liposomes. When comparing particle concentrations, we observed similar order values 
between liposome preparations included between 0.6 − 2 × 1012 particles per ml. A TLC 
analysis of lipids extracted from the liposomes revealed two sets of lipid species. The first 
set was found in all preparations including the ‘empty’ liposomes and were thus liposome 
derived (PC and Ch, shown). The other set of lipid species (shown by arrows) were of 
igure 2. Thin-layer chromatography (TLC) analyses of 0.8PC:0.2 h, B G and H37Rv liposomes.
10 µL of liposomes olution made in water were spotted and drie on a silica gel 60 F254 plate.
eparation oc urred in 60:16:2 CHCl3:MeOH: 2O solvent and was vi ualised by staining with
olybdophosphoric acid and charring. The arrows show t e presence of lipids from mycobacterial
origin. The data are from one repres ntative xperiment.
Visualisation of liposome particles using NanoSight NS300 optics and software was
used to define their size and distribution (Figure 1). Calibrated liposomes were generated
with an additional step of extrusion following sonication, producing: 0.8PC:0.2Ch lipo-
somes at 100 nm (Figure 1A) and 200 nm (Figure 1B), respectively. In parallel, 0.8PC:0.2Ch
liposomes were produced with a step of sonication only with no calibration (Figure 1C).
Two separate batches of M. bovis liposomes were generated (Figure 1D,E) and each mea-
sured on average 221.3 and 229 nm, respectively, hile the mean size of H37Rv liposomes
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(Figure 1F) was 201.7 nm. The similar sizes and distribution of the two independent prepa-
rations of M. bovis liposomes demonstrates the reproducibility of the liposome generation
technique. Due to a single sonication step, the population of M. bovis and H37Rv liposomes
generated is heterogenous compared to calibrated liposomes at 100 nm and 200 nm. Addi-
tionally, Mycobacterium liposomes appear larger than the calibrated liposomes [0.8PC:0.2Ch
100 nm (140.8 nm), 0.8PC:0.2Ch 200 nm (182.9 nm)] and 0.8PC:0.2Ch liposomes generated
with a single sonication step (171.4 nm, Figure 1C). This size variation is likely explained by
the incorporation of the Mycobacterium lipids onto M. bovis and H37Rv liposomes. When
comparing particle concentrations, we observed similar order values between liposome
preparations included between 0.6 − 2 × 1012 particles per ml. A TLC analysis of lipids
extracted from the liposomes revealed two sets of lipid species. The first set was found
in all preparations including the ‘empty’ liposomes and were thus liposome derived (PC
and Ch, shown). The other set of lipid species (shown by arrows) were of relatively lower
proportions and were only found in liposomes that were reconstituted with mycobacterial
lipids and thus were of mycobacterial origin (Figure 2). However, between M. bovis and
H37Rv we observed variation in the intensity of the lipid bands, suggesting differences in
lipid proportions contained in the liposomes. The analysis, therefore, demonstrates the
integration of specific Mycobacterium lipids into liposomes.
2.2. Mycobacterium Lipids Do Not Affect HIV-1 Cis-Infection
In order to measure the direct impact of Mtb liposomes on HIV-1 cis-infection (direct
infection), a non-productive HIV-1 pseudo-typed viral particle system (single round of
infection) was used in vitro. This system facilitates investigation into interaction or inter-
ference of HIV-1 entry and infection via the co-receptors CCR5 and CXCR4 in the presence
of Mycobacterium derived liposomes. To this end, two types of HIV-1 pseudo-typed viruses
were produced, expressing either HIV-1 LAI envelope (HIV-1 X4, utilisng CXCR4) or HIV-1
BAL envelope (HIV-1 R5, utilising CCR5).
The impact of 0.8PC:0.2Ch liposomes (containing PC and cholesterol only) on the
viability of the target cells used in this in vitro system (TZM-bl) were tested (Figure S1).
Control liposomes composed of a mix of PC and Ch did not affect TZM-bl viability after
48 h of incubation. Additionally, we observed that 0.8PC:0.2Ch liposomes did not interfere
with HIV-1 cis-infection compared to other liposomes compositions (Figure S2). For these
reasons, liposome produced in the ratio 0.6PC:0.2Ch:0.2Mycobacterium were chosen to build
liposomes incorporating Mycobacterium total lipid extracts.
The influence of Mycobacterium liposomes containing M. bovis, M. smegmatis, Mtb
H37Rv, HN878, CDC1551 and EU127 glycolipids was then assessed for modulating cis-
infection of TZM-bl cells using HIV-1 X4 and HIV-1 R5 viruses (Figure 3). Two conditions
were tested, where liposomes were added to cells at the same time as virus and where
liposomes were incubated with cells 30 min prior to infection. In order to compare results
from separate experiments, the raw relative light units (RLU) produced on every plate were
normalised to the average value of the negative control. For both viruses, in comparison
with TZM-bl cis-infection in the presence of 0.2PC:0.8Ch liposomes, we did not observe any
significant impact of Mtb liposomes under the two conditions, suggesting that the tested
glycolipids did not have the capacity to interfere with HIV-1 cell attachment and cell entry
via co-receptor recognition. Our results indicate that the derived liposomes described do
not alter HIV-1 direct infection of TZM-bl cells.
2.3. M. bovis, Mtb H37Rv and EU127 Lipids Interfere with HIV-1 Trans-Infection Mediated
by DC-SIGN
We next investigated the influence of Mtb lipids on HIV-1 trans-infection via binding
the DC-SIGN receptor using the same in vitro system of pseudo-typed virus particles
that allows a single-round of infection. In this assay, Raji-DC-SIGN cell lines were used
to support capture-transfer of HIV-1 R5 or X4 virions due to their expression of DC-
SIGN receptor and inability to be infected by the virus through lack of CD4 receptor
expression. Mycobacterial liposomes were pre-incubated with Raji-DC-SIGN before HIV-1
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X4 (Figure 4A) and HIV-1 R5 (Figure 4B) capture. The efficacy of capture-transfer of HIV-1
was normalised to the value of trans-infection in the presence of liposomes 0.8PC:0.2Ch
(negative control). We observed a strong inhibition of the efficacy of HIV-1 X4 and R5
trans-infection mediated by DC-SIGN receptor in the presence of M. bovis, Mtb H37Rv
and EU127 liposomes. Indeed, the non-pathogenic mycobacterial strain M. bovis inhibited
HIV-1 capture-transfer by 2.4-fold for HIV-1 X4 (p-value < 0.0001) and 1.9-fold for HIV-1
R5 (p-value = 0.0050). The Mtb pathogenic strain, H37Rv, strongly blocked trans-infection
of HIV-1 X4 and R5 virus by 5.2- and 3.4-fold respectively (p-value < 0.0001), and EU127 by
1.4-fold for HIV-1 X4 (p-value = 0.0009) and 1.5-fold for HIV-1 R5 (p-value < 0.0001).





Figure 3. Influence of Mycobacterium liposomes on HIV-1 cis-infection. Cells were infected with 8 
ng CA-p24 of (A,B) pSG3-LAI (HIV-1 X4), (C,D) pSG3-BAL (HIV-1 R5) and pSG3Δenv (ΔpSG3) 
where (A,C) virus input with 100 ng of liposomes at the same time or (B,D) 100 ng of liposomes 
added to TZM-bl cells 30 min prior to adding virus. 48 h after infection cells were lysed to measure 
luciferase activity (relative light unit, RLU). The RLUs produced for each experiment were nor-
malised to the average value of the negative control 0.8PC:0.2Ch liposomes. 0.8PC:0.2Ch is used 
here as a negative control and reference. For the data shown, n = 3. Mann–Whitney unpaired t-test 
was performed for (A–D). 
Conversely, only small and variable effects were observed for M. smegmatis, Mtb 
HN878 and CDC1551. Mtb HN878 increased trans-infection efficacy of HIV X4 by 1.2-fold 
(p-value = 0.0052), whilst there was no effect on X4 trans-infection by M. smegmatis or Mtb 
CDC1551 liposomes. Conversely, HIV-1 R5 trans-infection exhibited the opposite effect, 
whereby HN878 liposomes did not affect capture-transfer but M. smegmatis and Mtb 
CDC1551 liposomes increased the efficacy of R5 by 1.3-fold (p-value = 0.0190) and 1.2-fold 
(p-value = 0.0414), respectively. 
The impact of M. smegmatis, Mtb HN878 and CDC1551 total lipids on HIV-1 X4 and 
R5 trans-infection via DC-SIGN was minimal compared to the effect M. bovis, Mtb H37Rv 
and EU127, suggesting that glycolipids from these three strains could bind DC-SIGN 
thereby blocking virus trans-infection of the target cells. 
Figure 3. Influence of Mycobacterium liposomes on HIV-1 cis-infection. Cells were infected with 8 ng CA-p24 of (A,B) pSG3-
LAI (HIV-1 X4), (C,D) pSG3-BAL (HIV-1 R5) and pSG3∆env (∆pSG3) where (A,C) virus input with 100 ng of liposomes
at the same time or (B,D) 100 ng of liposomes added to TZM-bl cells 30 min prior to adding virus. 48 h after infection
cells were lysed to measure luciferase activity (relative light unit, RLU). The RLUs produced for each experiment were
normalised to the average value of the negative control 0.8PC:0.2Ch liposomes. 0.8PC:0.2Ch is used here as a negative
control and reference. For the data shown, n = 3. Mann–Whitney unpaired t-test was performed for (A–D).
Conversely, only small and variable effects were observed for M. smegmatis, Mtb
HN878 and CDC1551. Mtb HN878 increased trans-infection efficacy of HIV X4 by 1.2-fold
(p-value = 0.0052), whilst there was no effect on X4 trans-infection by M. smegmatis or
Mtb CDC1551 liposomes. Conversely, HIV-1 R5 trans-infection exhibited the opposite
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effect, whereby HN878 liposomes did not affect capture-transfer but M. smegmatis and Mtb
CDC1551 liposomes increased the efficacy of R5 by 1.3-fold (p-value = 0.0190) and 1.2-fold
(p-value = 0.0414), respectively.





Figure 4. Influence of the presence of Mycobacterium liposomes on HIV-1 trans-infection via Raji-DC-SIGN cells. (A) 12.5 
ng CA-p24 pSG3-LAI (HIV-1 X4) or (B) 20 ng CA-p24 pSG3-BAL (HIV-1 R5). After capture the cells were washed and co-
cultured with TZM-bl cells. The luciferase activity (RLU) was read after 48 h. The RLUs produced for each experiment 
were normalised to the average value of the negative control 0.8PC:0.2Ch liposomes. The data shown are a pool of at least 
two independent experiments where n ≥ 3 in total. Mann–Whitney unpaired t-test was performed for (A,B) and p- value 
represented with * for p-value < 0.05, ** for p-value < 0.01, *** for p-value < 0.001, **** for p-value < 0.0001. 
2.4. Implication of SL1, PDIM and TDM Lipids in HIV-1 trans-Infection Mediated by DC-
SIGN 
To further investigate the observed disruption of HIV-1 trans-infection by Mtb H37Rv 
glycolipids associated into liposomes, we compared the influence of total lipids from a 
variant H37Rv strain obtained from a different lab: H37RvMA (Figure 5) where the two 
lineages are differing in the number of local passage, inducing genotypic variation [74]. 
Raji-DC-SIGN were pre-incubated with liposomes prior to HIV-1 X4 (Figure 5A) or HIV-
1 R5 (Figure 5B) capture-transfer to TZM-bl cells. Interestingly, while the presence of 
H37RvAE liposomes decreased HIV-1 X4 and R5 trans-infection via DC-SIGN to 0.35 (p-
value = 0.0004) and 0.22 efficacy (p-value = 0.0004), H37RvMA did not affect virus capture-
transfer with a mean efficacy of 1.09 (HIV-1 X4) and 0.98 (HIV-1 R5). Specific mutations 
are observed in H37RvAE compared to H37RvMA, including mutation in ppsA that en-
codes a multidomain polyketide synthase involved in PDIM biosynthesis [74]. While 
mouse passaged H37Rv strains do produce PDIM, it is likely that variations in PDIM lev-
els occur in H37RvAE and H37RvMA liposomes, interfering with virus DC-SIGN receptor 
recognition. Given the low sensitivity of the TLC method in detecting the incorporated 
mycobacterial lipids (Figure 2), it is difficult to quantify this difference in PDIM levels in 
liposomes derived from the lipids of the two H37Rv strains. 
In order to identify glycolipids from Mtb H37Rv that influence HIV-1 trans-infection 
via DC-SIGN, total lipids from H37Rv were fractionated and the fractions obtained were 
associated into liposomes to assess their impact on HIV-1 trans-infection (Figure 6A). For 
both virus tropisms, we observed inhibition of virus capture-transfer via DC-SIGN with 
liposomes derived from fractions 2 and 4 by 6.4 and 5-fold for HIV-1 X4 and 14.5 and 6.6-
fold for HIV-1 R5, respectively. Fractions 1 and 5 liposomes also inhibited virus trans-
infection but with a weaker effect with a decrease of 1.4-fold for HIV-1 X4 and 1.2-fold for 
HIV-1 R5 and an inhibition of 1.8-fold for HIV-1 X4 and 1.5-fold for HIV-R5, respectively. 
The influence of liposomes made with fractions 1, 3 and 7 was variable between replicates 
and virus tropism. TLC analyses (Figure S3) revealed the presence of PDIM and SL in 
fraction 2 and TDM in fractions 4 to 7 where TDM concentration decreased through frac-
tionation. These results suggest that PDIM, SL and TDM are involved in disruption of DC-
SIGN mediated HIV-1 trans-infection. 
Figure 4. Influence of the presence of Mycobacterium liposomes on HIV-1 trans-infection via Raji-DC-SIGN cells. (A) 12.5 ng
CA-p24 pSG3-LAI (HIV-1 X4) or (B) 20 ng CA-p24 pSG3-BAL (HIV-1 R5). After capture the cells were washed and co-
cultured with TZM-bl cells. The luciferase activity (RLU) was read after 48 h. The RLUs produced for each experiment
were normalised to the average value of the negative control 0.8PC:0.2Ch liposomes. The data shown are a pool of at least
two independent experiments where n ≥ 3 in total. Mann–Whitney unpaired t-test was performed for (A,B) and p- value
represented with * for p-value < 0.05, ** for p-value < 0.01, *** for p-value < 0.001, **** for p-value < 0.0001.
The impact of M. smegmatis, Mtb HN878 and CDC1551 total lipids on HIV-1 X4 and R5
trans-infection via DC-SIGN was minimal compared to the effect M. b vis, Mtb H37Rv and
EU127, suggesting that glycolipids from these three strains could bind DC-SIGN thereby
blocking virus trans-infection of the target cells.
2.4. Implication of SL1, PDIM and TDM Lipids in HIV-1 Trans-Infection Mediated by DC-SIGN
To further investigate the observed disruption of HIV-1 trans-infection by Mtb H37Rv
glycolipids associated into liposomes, we compared the influence of total lipids from a
variant H37Rv strain obtained from a different lab: H37RvMA (Figure 5) where the two
lineages a differing in the numb of local passage, inducing genotypic variation [74]. Raji-
DC-SIGN were pre-incubated with liposomes prior to HIV-1 X4 (Figure 5A) or HIV-1 R5
(Figure 5B) capture-transfer to TZM-bl cells. Interestingly, while the presence of H37RvAE
liposomes decreased HIV-1 X4 and R5 trans-infection via DC-SIGN to 0.35 (p-value = 0.0004)
and 0.22 efficacy (p-value = 0.0004), H37RvMA did not affect virus capture-transfer with a
mean efficacy of 1.09 (HIV-1 X4) and 0.98 (HIV-1 R5). Specific mutations are observed in
H37RvAE compared to H37RvMA, including mutation in ppsA that encodes a multidomain
polyketide synthase involved in PDIM biosynthesis [74]. While mouse passaged H37Rv
strains do produce PDIM, it is likely that variations i PDIM levels occu in H37RvAE and
H37RvMA liposomes, interferi g with virus DC-SIGN receptor recognition. Giv n the low
sensitivity of the TLC method in detecting the incorporated mycobacterial lipids (Figure 2),
it is difficult to quantify this difference in PDIM levels in liposomes derived from the lipids
of the two H37Rv strains.
In order to identify glycolipids from Mtb H37Rv that influence HIV-1 trans-infection
via DC-SIGN, total lipids from H37Rv were fractionated and the fractions obtained were
associated into liposomes to assess their impact on HIV-1 trans-infection (Figure 6A). For
both virus tropisms, we observed inhibition of virus capture-transfer via DC-SIGN with
lip somes derived from fractions 2 an 4 b . -f l f r IV-1 X4 and 14.5 and
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6.6-fold for HIV-1 R5, respectively. Fractions 1 and 5 liposomes also inhibited virus trans-
infection but with a weaker effect with a decrease of 1.4-fold for HIV-1 X4 and 1.2-fold for
HIV-1 R5 and an inhibition of 1.8-fold for HIV-1 X4 and 1.5-fold for HIV-R5, respectively.
The influence of liposomes made with fractions 1, 3 and 7 was variable between replicates
and virus tropism. TLC analyses (Figure S3) revealed the presence of PDIM and SL in
fraction 2 and TDM in fractions 4 to 7 where TDM concentration decreased through
fractionation. These results suggest that PDIM, SL and TDM are involved in disruption of
DC-SIGN mediated HIV-1 trans-infection.





Figure 5. Comparison of the influence different H37Rv on HIV-1 trans-infection via Raji-DC-SIGN 
cells. (A) 12.5 ng CA-p24 pSG3-LAI (HIV-1 X4) or (B) 20 ng CA-p24 pSG3-BAL (HIV-1 R5). After 
capture the cells were washed and co-cultured with TZM-bl cells. The luciferase activity was read 
after 48 h. The RLUs produced for each experiment were normalised to the average value of the 
negative control 0.8PC:0.2Ch liposomes. The data shown are a pool of at least two independent 
experiments where n ≥ 6 in total. Mann–Whitney unpaired t-test was performed for (A,B) and p-
value represented with * for p-value < 0.05, ** for p-value < 0.01, *** for p-value < 0.001, **** for p-
value < 0.0001. 
The role of SL1 was further investigated by generating liposomes from total lipids 
isolated from an H37Rv papA1Δ mutant (mutant missing the polyketide associated-pro-
tein-1, papA1, involved in biogenesis of SL1 and resulting in the absence of SL1 produc-
tion) in parallel to liposomes with H37Rv papA1Δ total lipids complemented with soluble 
SL1 (Figure 6B). When we studied the impact of these liposomes on HIV-1 X4 (1) and HIV-
1 R5 (2) trans-infection mediated by DC-SIGN, we observed that papA1Δ liposomes only 
decreased virus capture-transfer by 1.1-fold for HIV-1 X4 (p-value = 0.0053) and 1.2-fold 
for HIV-1 R5 (p-value = 0.0030) while H37Rv blocked trans-infection via DC-SIGN by 3.2-
fold (p-value < 0.0001) for HIV-1 X4 and 3.1-fold (p-value < 0.0001) for HIV-1 R5. Interest-
ingly, liposomes composed of papA1Δ total lipids complemented with SL1 were shown 
to cause strong inhibition of 3.4-fold for HIV-1 X4 (p-value < 0.0001) and 4.1-fold for HIV-
1 R5 (p-value< 0.0001) trans-infection, indicating that SL1 expressed on H37Rv binds the 
DC-SIGN receptor, blocking HIV-1 trans-infection via this C-type lectin. 
2.5. Differential Effects of Mtb Glycolipids on HIV-1 Trans-Infection Mediated via iDC and 
mDC 
We next studied the impact of Mycobacterium liposomes on trans-infection of HIV-1 
via DCs, the physiological relevant cell-types mediating HIV-1 capture-transfer. DCs were 
pre-incubated with liposomes before capture and transfer of HIV-1 X4 or R5 by DCs at 
different stages of maturation: iDCs (Figure 7A,B) and mDCs (Figure 7C,D). Interestingly, 
as observed with the Raji-DC-SIGN in vitro assays, HIV-1 X4 and R5 iDC mediated trans-
infections were inhibited by 1.4- and 1.5-fold (pvalue = 0.0450) in the presence of M. bovis; 
by 1.8- (p-value = 0.0025) and 2.1-fold (p-value = 0.0002) in the presence of H37Rv; and by 
1.7- (p-value = 0.0011) and 1.6-fold (p-value = 0.0034) in the presence of EU127 liposomes, 
respectively. On the contrary, M. smegmatis, as well as Mtb HN878 and CDC1551 lipo-
somes showed a trend toward increasing HIV-1 trans-infection via iDCs by 1.6-fold (HIV-
1 R5); 1.3- (HIV-1 X4) and 1.5-fold (HIV-1 R5); and by 1.4- (HIV-1 X4) and 1.6-fold (HIV-1 
R5, p-value = 0.0220) respectively (Figure 7A,B). These observations suggest that M. bovis, 
Mtb H37Rv and EU127 glycolipids are recognised by the DC-SIGN receptor expressed on 
iDCs causing inhibition of HIV-1 capture and transfer to target cells. 
Figure 5. Comparison of the influence different H37Rv on HIV-1 trans-infection via Raji-DC-SIGN
cells. (A) 12.5 ng CA-p24 pSG3-LAI (HIV-1 X4) or (B) 20 ng CA-p24 pSG3-BAL (HIV-1 R5). After
capture the cells were washed and co-cultured with TZM-bl cells. The luciferase activity was read
after 48 h. The RLUs produced for each experiment were normalised to the average value of the
negative control 0.8PC:0.2Ch liposomes. The data shown are a pool of at least two independent
experiments where n ≥ 6 in total. Mann–Whitney unpaired t-test was performed for (A,B) and
p-value represented with * for p-value < 0.05, ** for p-value < 0.01, *** for p-value < 0.001, **** for
p-value < 0.0001.
The role of SL1 was further investigated by generating liposomes from total lipids
isolated from an H37Rv p pA1∆ muta t (mutan missin the polyketide a sociated-protein-
1, papA1, involved in biogenesis of SL1 and resulting in the absence of SL1 production)
in parallel to liposomes with H37Rv papA1∆ total lipids complemented with soluble SL1
(Figure 6B). When we studied the impact of these liposomes on HIV-1 X4 (1) and HIV-1
R5 (2) trans-infection mediated by DC-SIGN, we observed that papA1∆ liposomes only
decreased virus capture-transfer by 1.1-fold for HIV-1 X4 (p-value = 0.0053) and 1.2-fold for
HIV-1 R5 (p-value = 0.0030) while H37Rv blocked trans-infection via DC-SIGN by 3.2-fold
(p-value < 0.0001) for HIV-1 X4 and 3.1-fold (p-value < 0.0001) for HIV-1 R5. Interestingly,
liposomes com osed of papA1∆ total lipids complemented with SL1 were shown to cause
strong inhibition of 3.4-fold for HIV-1 X4 (p-value < 0.0001) and 4 1-fold I -1 R5 (p-
value< 0.0001) trans-infection, indicating that SL1 expressed on H37Rv binds the DC-SIGN
receptor, blocking HIV-1 trans-infection via this C-type lectin.
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into liposomes following the ratio 0.6PC:0.2Ch:0.2fraction and were tested on HIV-1 trans-infection via DC-SIGN in parallel
of 0.8PC:0.2Ch and H37Rv liposomes. The data shown are from one experiment, n = 3. (B) H37Rv papA1∆ and H37Rv
papA1∆ + SL1 were tested in parallel of 0.8PC:0.2Ch and H37Rv liposomes on HIV-1 trans-infection. The data shown are a
pool of at least two independent experiments where n ≥ 6 in total. For (A,B) 0.5 × 106 Raji DC-SIGN were pre-incubated
during 30 min with 100 µg liposomes or 50 µL of media. The cells were then incubated for 2 h with HIV-1 pseudo-typed
virus (1) 12.5 ng CA-p24 pSG3-LAI (HIV-1 X4) or (2) 20 ng CA-p24 pSG3-BAL (HIV-1 R5). After capture the cells were
washed and co-cultured with TZM-bl cells. The luciferase activity was read after 48 h. The RLUs produced for each
experiment were normalised to the average value of the negative control 0.8PC:0.2Ch liposomes. Mann–Whitney unpaired
t-test was performed for (A,B) and p-value represented with * for p-value < 0.05, ** for p-value < 0.01, *** for p-value < 0.001,
**** for p-value < 0.0001.
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2.5. Differential Effects of Mtb Glycolipids on HIV-1 Trans-Infection Mediated via iDC and mDC
We next studied the impact of Mycobacterium liposomes on trans-infection of HIV-1
via DCs, the physiological relevant cell-types mediating HIV-1 capture-transfer. DCs were
pre-incubated with liposomes before capture and transfer of HIV-1 X4 or R5 by DCs at
different stages of maturation: iDCs (Figure 7A,B) and mDCs (Figure 7C,D). Interestingly,
as observed with the Raji-DC-SIGN in vitro assays, HIV-1 X4 and R5 iDC mediated trans-
infections were inhibited by 1.4- and 1.5-fold (p-value = 0.0450) in the presence of M. bovis;
by 1.8- (p-value = 0.0025) and 2.1-fold (p-value = 0.0002) in the presence of H37Rv; and by
1.7- (p-value = 0.0011) and 1.6-fold (p-value = 0.0034) in the presence of EU127 liposomes,
respectively. On the contrary, M. smegmatis, as well as Mtb HN878 and CDC1551 liposomes
showed a trend toward increasing HIV-1 trans-infection via iDCs by 1.6-fold (HIV-1 R5);
1.3- (HIV-1 X4) and 1.5-fold (HIV-1 R5); and by 1.4- (HIV-1 X4) and 1.6-fold (HIV-1 R5,
p-value = 0.0220) respectively (Figure 7A,B). These observations suggest that M. bovis, Mtb
H37Rv and EU127 glycolipids are recognised by the DC-SIGN receptor expressed on iDCs
causing inhibition of HIV-1 capture and transfer to target cells.
In parallel, iDCs were grown in the presence of poly(I:C) to allow maturation into
mDCs and further used to mediate HIV-1 trans-infection to TZM-bl in the presence of
Mycobacterium liposomes (Figure 7C,D). Although we observed variant efficiency of virus
capture and transfer reflecting donor-to-donor variation, trends were observed when
comparing the different mycobacterial strains. The presence of M. bovis liposomes prior to
HIV-1 X4 and R5 capture-transfer via mDCs significantly inhibited the efficiency of trans-
infection by 1.3- (p-value = 0.0071) and 1.5-fold (p-value = 0.0047) respectively. Similarly,
H37Rv and CDC1551 liposomes blocked HIV-1 R5 viruses by 1.3- (p-value = 0.0052) and
1.6-fold (p-value = 0.0009) compared to the negative control 0.8PC:0.2Ch. For HN878, one
mDCs donor did exhibit heightened transfer of HIV-1 X4 by 2.5-fold and which seemed to
follow a trend of activation. Interestingly, cells from another donor showed an increase
of HIV-1 X4 trans-infection in the presence of M. smegmatis. There is a clear variation in
the impact of Mycobacterium liposomes on HIV-1 X4 and R5 trans-infection, depending on
the stage of DC maturation and virus tropism. These results suggest that the DC-SIGN
receptor is likely involved in HIV-1 DCs mediated trans-infection as well as other receptors
expressed by iDCs and mDCs, explaining variations between the cells types used.
The above is supported when analyzing the effect of mannan, a DC-SIGN receptor
antagonist, on HIV-1 trans-infection mediated by Raji-DC-SIGN, iDCs or mDCs (Figure S4).
We tested two different concentrations of mannan, which was pre-incubated with each
cell type prior to HIV-1 X4 trans-infection, as was performed for liposomes. We observed
that Raji-DC-SIGN HIV-1 X4 trans-infection of TZM-bl cells is strongly inhibited with both
concentrations of mannan tested with efficacy decreased to 0.16 with 20 µg/mL and in total
with 2 mg/mL of mannan compared to virus alone. Blocking the DC-SIGN receptor with
mannan on iDCs seems to not fully inhibit HIV-1 trans-infection. Indeed capture-transfer
was partially blocked and displayed a dose dependent effect: 20 µg/mL mannan reduced
efficacy by 1.5-fold and 2 mg/mL by 2.0-fold. Concerning capture-transfer via mDCs, we
did not observe any inhibition to HIV-1 X4 capture-transfer but an increase was observed
with 2 mg/mL by 1.6-fold. DC-SIGN recognition from antagonists such as mannan can
decrease HIV-1 trans-infection via iDCs whereas on mDCs, the DC-SIGN antagonist could
be seen to increase HIV-1 trans-infection at the highest concentration.
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Figure 7. Influence of Mycobacterium liposomes on HIV-1 trans-infection via iDCs or mDCs. (A) and (B) iDCS, (C,D) mDCs,
was pre-incubation for 30 min with 100 µg of liposomes or 50 µL of media. The cells were then incubated 2h with HIV-1
pseudo-typed virus: 12.5 ng CA-p24 pSG3-LAI (HIV-1 X4, panels (A,C)) or 20 ng CA-p24 pSG3-BAL (HIV-1 R5, panels
(B,D)). For the data shown, the experiment has been performed using cells isolated from on at least two different donors
where n ≥ 3 in total. The RLUs produced for each experiment were normalised to the average value of the negative control
0.8PC:0.2Ch liposomes. Mann–Whitney unpaired t-test was performed for (A–D) and p-value represented with * for p-value
< 0.05, ** for p-value < 0.01, *** for p-value < 0.001, **** for p-value < 0.0001.
3. Discussion
Here we investigated the role of Mycobacterium lipid extracts presented via liposomes
on influencing HIV-1 cis- and trans-infection. From this preliminary analysis of utilising
generated liposomes containing lipid extract antigen from variant pathogenic (e.g., Mtb
H37Rv, HN878, CDC1551 and EU127) and non-pathogenic (M. bovis and M. smegmatis)
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Mycobacterium strains we observed no difference between strains for influencing HIV-1 X4
or HIV-1 R5 direct infection of TZM-bl cells. The bacterial glycolipid antigens presented
on liposomes therefore did not interfere with direct HIV-1 entry to target cells via either
the CCR5 or CXCR4 co-receptor. This indicates that the interaction and binding of HIV-1
envelope protein sub-unit gp120 with CD4 receptor and co-receptors CCR5 and CXCR4
is not impacted by mycobacterial glycolipids. These results support that the mechanisms
involved in enhancement of HIV-1 replication observed in co-infected patient [75,76] is
most likely due to the modulation of the immune system by Mtb infection and do not
involve an increase of HIV-1 entry efficacy via direct interaction with Mtb components.
However, our data suggest that Mtb glycolipids potentially impair or enhance HIV-
1 trans-infection, where DCs capture and present virus to CD4 T cells, with important
implications for virus transmission and dissemination. The capture of infectious virions
and subsequent transmission to uninfected cells occurs by attachment of the glycoprotein
Env to DC receptors such as MR or DC-SIGN [8–10,13,77,78]. We demonstrate that trans-
infection of both R5 and X4 tropic HIV-1, mediated by DC-SIGN receptor, was impaired
in the presence of Mtb glycolipids from M. bovis, Mtb H37Rv and Mtb EU127 strains.
Unexpectedly, we identified TDM, SL1 and PDIM glycolipids to be involved in DC-SIGN
recognition and impairment of HIV-1 trans-infection by using Mtb H37Rv total lipids
fractionation. TDM is a major contributor of the immune simulation and is known to
interact with C-type lectin receptor Mincle expressed on macrophages [37,79] but not
DC-SIGN. Conversely, Mtb glycolipids PIMs, LM and LAM, identified to interact with
C-type lectin receptors due to their mannoside caps [49–51], present in fraction 8 on H37Rv
total lipids fractionation in our assays, did not show a clear impact on HIV-1 trans-infection
mediated by DC-SIGN receptor. Concerning SL1, its role in Mycobacterium pathogenicity
remains unclear [80,81]. In our model, we demonstrated using total lipids extract from the
H37Rv mutant papA1∆ associated into liposomes, that SL1 is critical in the inhibition of
DC-SIGN mediated HIV-1 trans-infection from Mtb H37Rv, suggesting SL1 interactions
with DC-SIGN receptor. Additionally, the comparison between H37RvMA strains and
H37RvAE differing from their origin and PDIM biosynthesis and composition [74], reveals
the implication of PDIM in DC-SIGN/SL1 interactions. Indeed, the impairment of HIV-1
DC-SIGN mediated trans-infection with glycolipids from H37RvAE is lost using liposomes
with total lipids extracted from H37RvMA. PDIM is known to be able to mask PAMPs to
escape from macrophage recognition [45,46,48], suggesting that in our system, high levels
of expression of PDIM in H37RvMA could mask SL1 interactions with DC-SIGN and not
interfere with virus capture. Nevertheless, the interaction of PDIM, SL1 and TDM with
DC-SIGN receptors remains to be characterised.
We tested the impact of the Mtb glycolipids associated into liposomes on HIV-1 trans-
infection mediated by DCs at different stage of maturation. Our findings indicate that M.
bovis, Mtb H37Rv and Mtb EU127 are able to inhibit HIV-1 trans-infection via iDCs. The
similar observations obtained on HIV-1 capture/transfer mediated by DC-SIGN, suggests
the involvement of DC-SIGN receptors in the inhibition of virus capture by iDC in the
presence of glycolipids from these strains. Conversely, M. smegmatis, Mtb HN878 and Mtb
CDC1551 liposomes showed a trend toward increasing HIV-1 trans-infection via iDCs.
These results suggest the involvement of receptors other than DC-SIGN, such as MR, in
Mtb antigen recognition, impacting HIV-1 trans-infection via mDC [10,11]. Moreover, the
stage of DCs maturation influences HIV-1 trans-infection, where mDCs are more efficient at
supporting virus trans-infection using different mechanisms compared to iDCs [19,82–84],
glycolipids from M. smegmatis, Mtb HN878 and CDC1551 could activate iDCs maturation
by pattern recognition receptors (PRRs) recognition and improve HIV-1 trans-infection
efficacy. Interestingly, the impact of Mtb liposomes on mDCs mediated HIV-1 trans-infection
varies from the experiments using iDCs. The variations observed between cell types
supports the hypothesis that receptors other than DC-SIGN can impact HIV-1 capture and
transfer and which can be differentially modulated by Mtb glycolipids. These complex
interactions between bacterial antigens and immune cells will undoubtedly influence the
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ensuing immune responses generated. HIV-1 trans-infection mediated by mDCs, involved
the receptor Siglec [16–20,84]. The influence reported here of Mtb liposomes on HIV-1
trans-infection mediated may be due to interactions with other PRRs, influencing Siglec
expression, or direct interaction with Siglec.
Collectively, our findings indicate that variant strains of Mtb can provide differential
effects on HIV-1 trans-infection which has the potential to influence HIV-1 disease course
in co-infected individuals. Studying HIV-1 trans-infection mediated via DC-SIGN receptor
represents a valuable alternative in vitro model to analyse DC-SIGN interactions with
bacterial glycolipid components. Additionally, liposomes technology represents a useful
technique to best mimic lipid distribution and antigen presentation on the mycobacterial
cell wall. The activation of PRR signaling pathways by Mtb PAMPs leads to the activa-
tion of HIV-1 replication and infection [85] through various mechanisms including the
modification/translocation of transcription factors [86,87], activation of NF-κB pathways,
or cytokine production [88–91]. Liposome technology will provide a means to study the
effects that Mtb antigens can exert on cell signaling and induction of immune responses
impacting HIV-1 infection, and more generally, the effect of bacterial antigens on the
immune responses.
4. Materials and Methods
4.1. Commercial Lipids
Cholesterol (Ch) and phosphatidylcholine (PC) were purchased from Sigma-Aldrich
(Sigma-Aldrich, St. Louis, MO, USA), and SL1 lipid solutions from BEI Resources.
4.2. M. Tuberculosis Strains and H37Rv Mutants
Mtb H37RvAE was used for all experiments unless otherwise mentioned. The EU127
Mtb strain was selected from a biobank of Mtb strains collected in a clinical study conducted
at the uBuntu clinic in Site B, Khayelitsha, a peri-urban township 30 km outside of Cape
Town, South Africa. Spoligotyping of this indicated that EU127 was a Beijing genotype.
The HN878, CDC1551 and H37RvMA Mtb isolates were propagated as part of the same
strain library and included as controls. H37RvAE ∆ papA1 was constructed by specialized
transduction as described [92].
Mtb glycerol stocks were inoculated into 10 mL of 7H9 (BD, Franklin Lakes, NJ, USA)
media with ADC (BD, Franklin Lakes, NJ, USA) and 0.05% Tween 80 (Sigma-Aldrich,
St. Louis, MO, USA) supplementation and cultured at 37◦ for 10 days, with gentle agitation
every two days. On day 10, 1 mL of this culture was used to inoculate 100 mL of 7H9
media with ADC supplementation (without Tween 80) and cultured for a further 10 days
at 37 ◦C without shaking. Cultures were centrifuged at 8000× rpm for 10 min to pellet the
cells. The supernatant was removed and discarded, and the pellet was resuspended in 1
mL of PBS. Mtb was killed by boiling cell suspensions at 80 ◦C for 1 h and used from lipid
extractions and preparation of liposomes.
4.3. Lipids Extractions
Total lipid extracts were obtained from culture pellet of M. bovis (BCG), M. smegmatis
(MC2155), Mtb H37Rv (H37RvAE), H37RvMA, H37RvAE ∆ papA1, HN878, CDC1551 and
EU127 following standard procedures as described [93]. Shortly, a solution of CHCl3:MeOH:
H2O was added to the bacterial pellet and kept at 50 ◦C for 3h. After centrifugation at
3000× g rpm, a mix of CHCl3:H2O was added to the supernatant and centrifuged after mix-
ing. The bottom phase obtained was then washed 2× g by with a mix of CHCl3:MeOH:H2O
(3:47:48 proportions) and heat at 55 ◦C to obtained a dry pellet.
For H37Rv (H37RvAE) lipids fractionation, 2 mg of total lipid extract from Mtb
H37RvAE was fractioned using a silica column. The column was pre-washed with chloro-
form (3× void volume) before the sample was added. Once the input sample was added
onto the column, 100 mL of chloroform was added to start flow through collection. A
mix of CHCl3:MeOH solvent was passed through the column with a progressive increase
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in the proportion of methanol (99:1, 1–8 collection tubes; 98:2, 9–15 collection tubes; 97:3,
16–23 collection tubes; 95:5, 24–31 collection tubes; 93:7, 32–49 collection tubes; 90:10, 50–57
collection tubes and 80:20, 58–63 collection tubes). For the analyses of H37RvAE, collection
tubes 1 to 9 were pooled as Fraction 1; 10 to 13 pooled as Fraction 2; 14 to 18 pooled as
Fraction 3; 19 to 27 pooled as Fraction 4; 28 to 32 pooled as Fraction 5; 33 to 36 pooled as
Fraction 6, 37 to 44 pooled as Fraction 7 and 45 to 63 pooled as Fraction 8.
4.4. Liposomes
All dried lipid pellets were solubilised in CHCl3:MeOH (2:1 proportion) and PC and
Ch were solubilised in chloroform. Liposomes were generated with a mix of PC and Ch in
0.8PC:0.2Ch proportion for liposomes without Mycobacterium lipids; a mix of PC, Ch and
total lipids extracted from BCG, MC2155, H37RvAE, H37RvMA, H37Rv papA1∆, H37RvAE
Fractions, HN878, CDC1551 and EU127 in 0.6PC:0.2Ch:0.2 Mycobacterium proportion; a
mix of PC, Ch, H37Rv papA1∆ and SL1 lipids in 0.6PC:0.2Ch:1.9:0.1SL1; or a mix of PC,
Ch and PDIM lipids in 7.8PC:0.2Ch:0.2PDIM proportion. After the different lipids were
mixed together in chloroform solution (2 mg in total), the chloroform was then evaporated
with nitrogen gas for 30 min forming a film of dried lipids. Liposomes were hydrated
by addition of Roswell Park Memorial Institute (RPMI-1640, Thermo Fisher Scientific,
Waltham, MA, USA), Dulbecco Modified Eagle Medium (DMEM, Thermo Fisher Scientific,
Waltham, MA, USA), Phosphate-Buffered Saline (PBS, Thermo Fisher Scientific, Waltham,
MA, USA), or sterile water. Liposomes were then incubated at 55 ◦C for 30 min with
vortexing (final concentration 10 mg/mL). The preparations were subsequently sonicated
for 30 min at 4 ◦C.
For NanoSight analyses of liposomes, 0.8PC:0.2Ch liposomes were filtered using the
Avanti® Mini-Extruder system after sonication. Liposome solutions were filtered through
a 100 or 200 nm polycarbonate filter under 50 ◦C temperature to produce 100 and 200 nm
0.8PC:0.2Ch liposome diameters.
4.5. Liposomes Characterisation
For TLC analyses, 10 µL of 0.8PC:0.2Ch, BCG and H37RvAE liposomes made in sterile
water, SL, TDM, PIMs, PDIM lipid solution or H37RvAE lipid Fractions 1 to 8 were spotted
and dried on a silica gel 60 F254 plate (Sigma-Aldrich, St. Louis, MO, USA). Sample
separation occurred in 60:16:2 CHCl3:MeOH:H2O solvent and was visualised by staining
with molybdophosphoric acid (MPA) and charring.
Visualisation, particle concentration and the size distribution of the generated lipo-
somes were evaluated using the NanoSight NS300 instrument (Malvern Panatical, Malvern,
UK) and using Nanoparticle Tracking Analysis (NTA) software. Videos were recording at
camera level 13. The post-acquisition settings were with a minimum detection threshold
7, automatic blur and automatic minimum expected particle size. 0.8PC:0.2Ch, BCG and
H37RvAE liposome made in PBS were diluted 1:1000–1:2000 in PBS for each sample and
three 60 s videos were recorded and analysed.
4.6. Cells
293T and TZM-bl (NIH AIDS) cells were maintained at 37 ◦C 5% CO2 in DMEM
supplemented with 10% FBS, L-glutamine, 100 U/mL penicillin and 100 mg/mL strep-
tomycin. Raji-DC-SIGN (NIH AIDS) were cultured at 37 ◦C 5% CO2 in RPMI-1640 con-
taining L-glutamine, supplemented with 10% FBS, 100 U/mL penicillin and 100 mg/mL
streptomycin.
Human blood monocytes were isolated in buffy coats from healthy donors by using
Ficoll gradient and a subsequent CD14 selection step using the MACS system (Miltenyi
Biotec, Bergisch Gladbach, Germany). Purified monocytes were cultured RPMI-1640 con-
taining L-glutamine supplemented with 10% FBS serum 100 U/mL penicillin, 100 mg/mL
streptomycin, 70 ng/mL human IL-4 (Thermo Fisher Scientific, Waltham, MA, USA) and
50 ng/mL human GM-CSF (Thermo Fisher Scientific, Waltham, MA, USA) for differentia-
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tion into immature dendritic cells (iDC). The iDCs were harvested after 6 days of incubation.
Mature monocyte derived dendritic cells (mDCs) were isolated from fresh iDCs. At day
620 µg/mL of Poly(I:C) (Sigma-Aldrich, St. Louis, MO, USA) was added to iDCs media.
The mDCs cells were harvested after 18–24 h of incubation at 37 ◦C, 5% CO2.
4.7. Cell Viability in the Presence of Liposomes
3 × 104 TZM-bl cells in 250 µL media per well were seeded in 96-well plates. After
24 h at 37 ◦C 5% CO2, the cells were incubated with 1000, 100, 10 and 1 ng of 0.8PC:0.2Ch
liposomes in 250 µL total volume. After 48 h incubation at 37 ◦C 5% CO2 the media was
removed and the cells harvested via trypsin treatment and fixed in 2% PFA (Sigma-Aldrich,
St. Louis, MO, USA). After fixation, the cells were re-suspended in PBS and the viability
was analysed by standard flow cytometry measuring forward and side scatter to determine
live from dead cell populations. BD AccuriTM C6 was used to record 10,000 events for
each sample and data analysis was performed using the BD AccuriTM C6 Plus software.
Furthermore, no differences in cell recoveries were observed following culturing in the
presence of the variant concentrations of liposomes.
4.8. Virus Production
One day prior to transfection 1.2 × 106 293T cells were seeded in a 10 cm dish in
8 mL of media. After 24 h, the cells were transfected using the Lipofectamine standard
method where 2 µg of HIV-1 envelope plasmid BAL (R5 tropism, NIH AIDS) or LAI (X4
tropism, NIH AIDS), and 2 µg of the backbone pSG3∆env plasmid (NIH AIDS) were mixed
in 300 µL of OptiMEM (Thermo Fisher Scientific, Waltham, MA, USA). Separately, 24 µL
of Lipofectamine was mixed with 276 µL of OptiMEM and 300 µL of this was added
to the DNA mix. After 30 min incubation at RT, the Lipofectamine/DNA mixture was
added dropwise to 293T cells with 1 mL of OptiMEM. After 6h, the media was replaced
with fresh DMEM and the pseudo-typed virus stock (supernatant) was harvested after
further 48 h of incubation at 37 ◦C 5% CO2. Viruses were stored at −80 ◦C and virus
concentrations were quantified by measuring CA-p24 antigen levels by ELISA (Aalto Bio
Reagents, Dublin, Ireland).
4.9. HIV-1 Cis-Infection
One day prior to infection, 3 × 104 TZM-bl cells in 250 µL of media per well were
seeded in 96-well plates. In scenario one, liposomes suspension in DMEM was added to
the cells at the same time virus was added. 8ng CA-p24 of pSG3-LAI, pSG3-BAL pseudo-
typed virus was mixed with 100 ng liposomes in 50 µL total volume and added to the
TZM-bl cells. After 2 h incubation at 37 ◦C 5% CO2, 200 µL of media was added and the
infection measured after 48 h. In the second scenario, liposome suspensions in DMEM
were added to the cells prior to virus input. 50 µL of 100ng of liposome was added to the
TZM-bl cells. After 30 min incubation at 37 ◦C and 5% CO2, 8 ng CA-p24 of pSG3-LAI
or pSG3-BAL pseudo-typed virus was added and incubated for 2 h as described above.
Following this incubation, 200 µL of media was added to each well and incubated for 48 h.
For both scenarios, after 48 h of infection the cells were washed with PBS, and 20 µL of
lysis Buffer (Promega, Madison, WI, USA) was added per well. Luciferase activity was
determined using the Luciferase Assay kit (Promega, Madison, WI, USA) and FLUOStar
Omega luminometer (BMG LabTech, Ortenberg, Germany) following the manufacturer’s
instructions. Infections with pSG3∆env virus were used as negative control.
4.10. HIV-1 Trans-Infection
One day prior to capture/transfer, 3× 104 TZM-bl cells per well were seeded on 96-well
plates and cultured overnight. Prior virus capture, 0.5 × 106 Raji DC-SIGN, iDCs or mDCs
cells were pelleted and mixed with 100 µg of liposomes in RPMI-1640 suspension. After
30 min incubation at 37 ◦C 5% CO2, 12.5 ng CA-p24 pSG3∆env, 12.5 ng CA-p24 pSG3-LAI
or 25 ng CA-p24 of pSG3-BAL were added to cells for 2 h at 37 ◦C 5% CO2. The cells were
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then washed 4× with cold PBS and re-suspended in 45 µL of DMEM containing 30 ng/mL
of Dextran. Finally, 15 µL of the suspension was used per well to infect TZM-bl cells. After
48 h at 37 ◦C 5% CO2, the TZM-bl cells were lysed and luciferase activity measured as
described above. Infection with pSG3∆env virus were used as negative control.
4.11. Statistical Analysis
For all results, unpaired sample comparisons were performed using the non-parametric
rank test Mann–Whitney and depict in Figures using the following: * for p-value < 0.05,
** for p-value < 0.01, *** for p-value < 0.001, **** for p-value < 0.0001. Data are represented
in boxplot where the box extends from the 25th and 75th percentiles, the median is plotted
at the line in the middle of the box, the whiskers represent the minimum and maximum
value. All statistical analyses were performed with the Prism software.
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Ch Cholesterol
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mDC Mature dendritic cell
MR Mannose receptor
Mtb Mycobacterium tuberculosis
PAMPs Pathogen associated molecular patterns













1. World Health Organization Global Tuberculosis Report; WHO: Geneva, Switzerland, 2020.
2. Sullivan, Z.A.; Wong, E.B.; Ndung’u, T.; Kasprowicz, V.O.; Bishai, W.R. Latent and Active Tuberculosis Infection Increase Immune
Activation in Individuals Co-Infected with HIV. EBioMedicine 2015, 2, 334–340. [CrossRef]
3. Bell, L.C.K.; Noursadeghi, M. Pathogenesis of HIV-1 and Mycobacterium tuberculosis co-infection. Nat. Rev. Microbiol. 2018, 16,
80–90. [CrossRef] [PubMed]
4. Waters, R.; Ndengane, M.; Abrahams, M.-R.; Diedrich, C.R.; Wilkinson, R.J.; Coussens, A.K. The Mtb-HIV syndemic interaction:
Why treating M. tuberculosis infection may be crucial for HIV-1 eradication. Future Virol. 2020, 15, 101–125. [CrossRef]
5. Naqvi, K.F.; Endsley, J.J. Myeloid C-Type Lectin Receptors in Tuberculosis and HIV Immunity: Insights Into Co-infection? Front.
Cell. Infect. Microbiol. 2020, 10, 263. [CrossRef]
6. Nguyen, D.G.; Hildreth, J.E.K. Involvement of macrophage mannose receptor in the binding and transmission of HIV by
macrophages. Eur. J. Immunol. 2003, 33, 483–493. [CrossRef] [PubMed]
7. Cameron, P.U.; Freudenthal, P.S.; Barker, J.M.; Gezelter, S.; Inaba, K.; Steinman, R.M. Dendritic cells exposed to human
immunodeficiency virus type-1 transmit a vigorous cytopathic infection to CD4+ T cells. Science 1992, 257, 383–387. [CrossRef]
[PubMed]
8. Gummuluru, S.; KewalRamani, V.N.; Emerman, M. Dendritic cell-mediated viral transfer to T cells is required for human
immunodeficiency virus type 1 persistence in the face of rapid cell turnover. J. Virol. 2002, 76, 10692–10701. [CrossRef]
9. Garcia, E.; Pion, M.; Pelchen-Matthews, A.; Collinson, L.; Arrighi, J.F.; Blot, G.; Leuba, F.; Escola, J.M.; Demaurex, N.; Marsh, M.;
et al. HIV-1 trafficking to the dendritic cell-T-cell infectious synapse uses a pathway of tetraspanin sorting to the immunological
synapse. Traffic 2005, 6, 488–501. [CrossRef] [PubMed]
10. Sallusto, F.; Cella, M.; Danieli, C.; Lanzavecchia, A. Dendritic cells use macropinocytosis and the mannose receptor to concentrate
macromolecules in the major histocompatibility complex class II compartment: Downregulation by cytokines and bacterial
products. J. Exp. Med. 1995, 182, 389–400. [CrossRef]
11. Turville, S.G.; Cameron, P.U.; Handley, A.; Lin, G.; Pöhlmann, S.; Doms, R.W.; Cunningham, A.L. Diversity of receptors binding
HIV on dendritic cell subsets. Nat. Immunol. 2002, 3, 975–983. [CrossRef]
12. Geijtenbeek, T.B.; Kwon, D.S.; Torensma, R.; van Vliet, S.J.; van Duijnhoven, G.C.; Middel, J.; Cornelissen, I.L.M.H.; Nottet, H.S.L.;
KewalRamani, V.N.; Littman, D.R.; et al. DC-SIGN, a dendritic cell-specific HIV-1-binding protein that enhances trans-infection
of T cells. Cell 2000, 100, 587–597. [CrossRef]
13. Turville, S.; Wilkinson, J.; Cameron, P.; Dable, J.; Cunningham, A.L. The role of dendritic cell C-type lectin receptors in HIV
pathogenesis. J. Leukoc. Biol. 2003, 74, 710–718. [CrossRef] [PubMed]
14. Moris, A.; Pajot, A.; Blanchet, F.; Guivel-Benhassine, F.; Salcedo, M.; Schwartz, O. Dendritic cells and HIV-specific CD4+ T cells:
HIV antigen presentation, T-cell activation, and viral transfer. Blood 2006, 108, 1643–1651. [CrossRef]
15. Van Montfort, T.; Nabatov, A.A.; Geijtenbeek, T.B.H.; Pollakis, G.; Paxton, W.A. Efficient capture of antibody neutralized HIV-1 by
cells expressing DC-SIGN and transfer to CD4+ T lymphocytes. J. Immunol. 2007, 178, 3177–3185. [CrossRef] [PubMed]
16. Bobardt, M.D.; Saphire, A.C.S.; Hung, H.-C.; Yu, X.; Van der Schueren, B.; Zhang, Z.; David, G.; Gallay, P.A. Syndecan captures,
protects, and transmits HIV to T lymphocytes. Immunity 2003, 18, 27–39. [CrossRef]
17. De Witte, L.; Bobardt, M.; Chatterji, U.; Degeest, G.; David, G.; Geijtenbeek, T.B.H.; Gallay, P. Syndecan-3 is a dendritic cell-specific
attachment receptor for HIV-1. Proc. Natl. Acad. Sci. USA 2007, 104, 19464–19469. [CrossRef]
18. Puryear, W.B.; Yu, X.; Ramirez, N.P.; Reinhard, B.M.; Gummuluru, S. HIV-1 incorporation of host-cell-derived glycosphingolipid
GM3 allows for capture by mature dendritic cells. Proc. Natl. Acad. Sci. USA 2012, 109, 7475–7480. [CrossRef]
19. Izquierdo-Useros, N.; Lorizate, M.; McLaren, P.J.; Telenti, A.; Kräusslich, H.-G.; Martinez-Picado, J. HIV-1 capture and transmission
by dendritic cells: The role of viral glycolipids and the cellular receptor Siglec-1. PLoS Pathog. 2014, 10, e1004146. [CrossRef]
20. Akiyama, H.; Ramirez, N.-G.P.; Gudheti, M.V.; Gummuluru, S. CD169-mediated trafficking of HIV to plasma membrane
invaginations in dendritic cells attenuates efficacy of anti-gp120 broadly neutralizing antibodies. PLoS Pathog. 2015, 11, e1004751.
[CrossRef]
Int. J. Mol. Sci. 2021, 22, 1945 18 of 21
21. Hoffmann, C.; Leis, A.; Niederweis, M.; Plitzko, J.M.; Engelhardt, H. Disclosure of the mycobacterial outer membrane: Cryo-
electron tomography and vitreous sections reveal the lipid bilayer structure. Proc. Natl. Acad. Sci. USA 2008, 105, 3963–3967.
[CrossRef]
22. Zuber, B.; Chami, M.; Houssin, C.; Dubochet, J.; Griffiths, G.; Daffé, M. Direct visualization of the outer membrane of mycobacteria
and corynebacteria in their native state. J. Bacteriol. 2008, 190, 5672–5680. [CrossRef]
23. Angala, S.K.; Belardinelli, J.M.; Huc-Claustre, E.; Wheat, W.H.; Jackson, M. The cell envelope glycoconjugates of Mycobacterium
tuberculosis. Crit. Rev. Biochem. Mol. Biol. 2014, 49, 361–399. [CrossRef] [PubMed]
24. Bansal-Mutalik, R.; Nikaido, H. Mycobacterial outer membrane is a lipid bilayer and the inner membrane is unusually rich in
diacyl phosphatidylinositol dimannosides. Proc. Natl. Acad. Sci. USA 2014, 111, 4958–4963. [CrossRef]
25. Grzegorzewicz, A.E.; de Sousa-d’Auria, C.; McNeil, M.R.; Huc-Claustre, E.; Jones, V.; Petit, C.; Angala, S.K.; Zemanová, J.; Wang,
Q.; Belardinelli, J.M.; et al. Assembling of the Mycobacterium tuberculosis Cell Wall Core. J. Biol. Chem. 2016, 291, 18867–18879.
[CrossRef]
26. Singh, P.; Rameshwaram, N.R.; Ghosh, S.; Mukhopadhyay, S. Cell envelope lipids in the pathophysiology of Mycobacterium
tuberculosis. Future Microbiol. 2018, 13, 689–710. [CrossRef] [PubMed]
27. Barry, C.E.; Lee, R.E.; Mdluli, K.; Sampson, A.E.; Schroeder, B.G.; Slayden, R.A.; Yuan, Y. Mycolic acids: Structure, biosynthesis
and physiological functions. Prog. Lipid Res. 1998, 37, 143–179. [CrossRef]
28. Dubnau, E.; Chan, J.; Raynaud, C.; Mohan, V.P.; Lanéelle, M.A.; Yu, K.; Quémard, A.; Smith, I.; Daffé, M. Oxygenated mycolic
acids are necessary for virulence of Mycobacterium tuberculosis in mice. Mol. Microbiol. 2000, 36, 630–637. [CrossRef] [PubMed]
29. Vander Beken, S.; Al Dulayymi, J.R.; Naessens, T.; Koza, G.; Maza-Iglesias, M.; Rowles, R.; Theunissen, C.; De Medts, J.;
Lanckacker, E.; Baird, M.S.; et al. Molecular structure of the Mycobacterium tuberculosis virulence factor, mycolic acid, determines
the elicited inflammatory pattern. Eur. J. Immunol. 2011, 41, 450–460. [CrossRef]
30. Dkhar, H.K.; Nanduri, R.; Mahajan, S.; Dave, S.; Saini, A.; Somavarapu, A.K.; Arora, A.; Parkesh, R.; Thakur, K.G.; Mayilraj,
S.; et al. Mycobacterium tuberculosis Keto-Mycolic Acid and Macrophage Nuclear Receptor TR4 Modulate Foamy Biogenesis in
Granulomas: A Case of a Heterologous and Noncanonical Ligand-Receptor Pair. J. Immunol. 2014, 193, 295–305. [CrossRef]
[PubMed]
31. Means, T.K.; Wang, S.; Lien, E.; Yoshimura, A.; Golenbock, D.T.; Fenton, M.J. Human toll-like receptors mediate cellular activation
by Mycobacterium tuberculosis. J. Immunol. 1999, 163, 3920–3927.
32. Ryll, R.; Watanabe, K.; Fujiwara, N.; Takimoto, H.; Hasunuma, R.; Kumazawa, Y.; Okada, M.; Yano, I. Mycobacterial cord factor,
but not sulfolipid, causes depletion of NKT cells and upregulation of CD1d1 on murine macrophages. Microbes Infect. 2001, 3,
611–619. [CrossRef]
33. Geisel, R.E.; Sakamoto, K.; Russell, D.G.; Rhoades, E.R. In vivo activity of released cell wall lipids of Mycobacterium bovis
bacillus Calmette-Guérin is due principally to trehalose mycolates. J. Immunol. 2005, 174, 5007–5015. [CrossRef] [PubMed]
34. Linares, C.; Bernabéu, A.; Luquin, M.; Valero-Guillén, P.L. Cord factors from atypical mycobacteria (Mycobacterium alvei,
Mycobacterium brumae) stimulate the secretion of some pro-inflammatory cytokines of relevance in tuberculosis. Microbiology 2012,
158, 2878–2885. [CrossRef] [PubMed]
35. Welsh, K.J.; Hunter, R.L.; Actor, J.K. Trehalose 6,6′-dimycolate—A coat to regulate tuberculosis immunopathogenesis. Tuberculosis
(Edinb.) 2013, 93, S3–S9. [CrossRef]
36. Indrigo, J.; Hunter, R.L.; Actor, J.K. Influence of trehalose 6,6′-dimycolate (TDM) during mycobacterial infection of bone marrow
macrophages. Microbiology 2002, 148, 1991–1998. [CrossRef]
37. Ishikawa, E.; Ishikawa, T.; Morita, Y.S.; Toyonaga, K.; Yamada, H.; Takeuchi, O.; Kinoshita, T.; Akira, S.; Yoshikai, Y.; Yamasaki,
S. Direct recognition of the mycobacterial glycolipid, trehalose dimycolate, by C-type lectin Mincle. J. Exp. Med. 2009, 206,
2879–2888. [CrossRef]
38. Kan-Sutton, C.; Jagannath, C.; Hunter, R.L. Trehalose 6,6′-dimycolate on the surface of Mycobacterium tuberculosis modulates
surface marker expression for antigen presentation and costimulation in murine macrophages. Microbes Infect. 2009, 11, 40–48.
[CrossRef] [PubMed]
39. Hamasaki, N.; Isowa, K.; Kamada, K.; Terano, Y.; Matsumoto, T.; Arakawa, T.; Kobayashi, K.; Yano, I. In vivo administration of
mycobacterial cord factor (Trehalose 6,6′-dimycolate) can induce lung and liver granulomas and thymic atrophy in rabbits. Infect.
Immun. 2000, 68, 3704–3709. [CrossRef] [PubMed]
40. Sakamoto, K.; Kim, M.J.; Rhoades, E.R.; Allavena, R.E.; Ehrt, S.; Wainwright, H.C.; Russell, D.G.; Rohde, K.H. Mycobacterial
trehalose dimycolate reprograms macrophage global gene expression and activates matrix metalloproteinases. Infect. Immun.
2013, 81, 764–776. [CrossRef]
41. Converse, S.E.; Mougous, J.D.; Leavell, M.D.; Leary, J.A.; Bertozzi, C.R.; Cox, J.S. MmpL8 is required for sulfolipid-1 biosynthesis
and Mycobacterium tuberculosis virulence. Proc. Natl. Acad. Sci. USA 2003, 100, 6121–6126. [CrossRef]
42. Domenech, P.; Reed, M.B.; Dowd, C.S.; Manca, C.; Kaplan, G.; Barry, C.E. The role of MmpL8 in sulfatide biogenesis and virulence
of Mycobacterium tuberculosis. J. Biol. Chem. 2004, 279, 21257–21265. [CrossRef]
43. Goren, M.B.; Brokl, O.; Schaefer, W.B. Lipids of putative relevance to virulence in Mycobacterium tuberculosis: Phthiocerol
dimycocerosate and the attenuation indicator lipid. Infect. Immun. 1974, 9, 150–158. [CrossRef] [PubMed]
44. Cox, J.S.; Chen, B.; McNeil, M.; Jacobs, W.R. Complex lipid determines tissue-specific replication of Mycobacterium tuberculosis in
mice. Nature 1999, 402, 79–83. [CrossRef]
Int. J. Mol. Sci. 2021, 22, 1945 19 of 21
45. Astarie-Dequeker, C.; Le Guyader, L.; Malaga, W.; Seaphanh, F.-K.; Chalut, C.; Lopez, A.; Guilhot, C. Phthiocerol dimycocerosates
of M. tuberculosis participate in macrophage invasion by inducing changes in the organization of plasma membrane lipids. PLoS
Pathog. 2009, 5, e1000289. [CrossRef] [PubMed]
46. Quigley, J.; Hughitt, V.K.; Velikovsky, C.A.; Mariuzza, R.A.; El-Sayed, N.M.; Briken, V. The Cell Wall Lipid PDIM Contributes to
Phagosomal Escape and Host Cell Exit of Mycobacterium tuberculosis. mBio 2017, 8, e00148-17. [CrossRef]
47. Rousseau, C.; Winter, N.; Pivert, E.; Bordat, Y.; Neyrolles, O.; Avé, P.; Huerre, M.; Gicquel, B.; Jackson, M. Production of phthiocerol
dimycocerosates protects Mycobacterium tuberculosis from the cidal activity of reactive nitrogen intermediates produced by
macrophages and modulates the early immune response to infection. Cell. Microbiol. 2004, 6, 277–287. [CrossRef]
48. Cambier, C.J.; Takaki, K.K.; Larson, R.P.; Hernandez, R.E.; Tobin, D.M.; Urdahl, K.B.; Cosma, C.L.; Ramakrishnan, L. Mycobacteria
manipulate macrophage recruitment through coordinated use of membrane lipids. Nature 2014, 505, 218–222. [CrossRef]
[PubMed]
49. Koppel, E.A.; Ludwig, I.S.; Sanchez Hernandez, M.; Lowary, T.L.; Gadikota, R.R.; Tuzikov, A.B.; Vandenbroucke-Grauls, C.M.J.E.;
van Kooyk, Y.; Appelmelk, B.J.; Geijtenbeek, T.B.H. Identification of the mycobacterial carbohydrate structure that binds the
C-type lectins DC-SIGN, L-SIGN and SIGNR1. Immunobiology 2004, 209, 117–127. [CrossRef]
50. Pitarque, S.; Herrmann, J.-L.; Duteyrat, J.-L.; Jackson, M.; Stewart, G.R.; Lecointe, F.; Payre, B.; Schwartz, O.; Young, D.B.; Marchal,
G.; et al. Deciphering the molecular bases of Mycobacterium tuberculosis binding to the lectin DC-SIGN reveals an underestimated
complexity. Biochem. J. 2005, 392, 615–624. [CrossRef]
51. Driessen, N.N.; Ummels, R.; Maaskant, J.J.; Gurcha, S.S.; Besra, G.S.; Ainge, G.D.; Larsen, D.S.; Painter, G.F.; Vandenbroucke-
Grauls, C.M.J.E.; Geurtsen, J.; et al. Role of Phosphatidylinositol Mannosides in the Interaction between Mycobacteria and
DC-SIGN. Infect. Immun. 2009, 77, 4538–4547. [CrossRef] [PubMed]
52. Vignal, C.; Guérardel, Y.; Kremer, L.; Masson, M.; Legrand, D.; Mazurier, J.; Elass, E. Lipomannans, but not lipoarabinomannans,
purified from Mycobacterium chelonae and Mycobacterium kansasii induce TNF-α and IL-8 secretion by a CD14-toll-like receptor
2-dependent mechanism. J. Immunol. 2003, 171, 2014–2023. [CrossRef]
53. Quesniaux, V.J.; Nicolle, D.M.; Torres, D.; Kremer, L.; Guérardel, Y.; Nigou, J.; Puzo, G.; Erard, F.; Ryffel, B. Toll-like recep-
tor 2 (TLR2)-dependent-positive and TLR2-independent-negative regulation of proinflammatory cytokines by mycobacterial
lipomannans. J. Immunol. 2004, 172, 4425–4434. [CrossRef]
54. Gilleron, M.; Nigou, J.; Nicolle, D.; Quesniaux, V.; Puzo, G. The acylation state of mycobacterial lipomannans modulates innate
immunity response through toll-like receptor 2. Chem. Biol. 2006, 13, 39–47. [CrossRef]
55. Doz, E.; Rose, S.; Nigou, J.; Gilleron, M.; Puzo, G.; Erard, F.; Ryffel, B.; Quesniaux, V.F.J. Acylation determines the toll-like receptor
(TLR)-dependent positive versus TLR2-, mannose receptor-, and SIGNR1-independent negative regulation of pro-inflammatory
cytokines by mycobacterial lipomannan. J. Biol. Chem. 2007, 282, 26014–26025. [CrossRef] [PubMed]
56. Puissegur, M.-P.; Lay, G.; Gilleron, M.; Botella, L.; Nigou, J.; Marrakchi, H.; Mari, B.; Duteyrat, J.-L.; Guerardel, Y.; Kremer, L.; et al.
Mycobacterial lipomannan induces granuloma macrophage fusion via a TLR2-dependent, ADAM9- and β1 integrin-mediated
pathway. J. Immunol. 2007, 178, 3161–3169. [CrossRef]
57. Guenin-Macé, L.; Siméone, R.; Demangel, C. Lipids of Pathogenic Mycobacteria: Contributions to Virulence and Host Immune
Suppression. Transbound. Emerg. Dis. 2009, 56, 255–268. [CrossRef] [PubMed]
58. Daffé, M.; Crick, D.C.; Jackson, M. Genetics of Capsular Polysaccharides and Cell Envelope (Glyco)lipids. Microbiol. Spectr. 2014,
2, MGM2-0021-2013. [CrossRef] [PubMed]
59. Lin, Y.; Zhang, M.; Barnes, P.F. Chemokine production by a human alveolar epithelial cell line in response to Mycobacterium
tuberculosis. Infect. Immun. 1998, 66, 1121–1126. [CrossRef] [PubMed]
60. Theus, S.A.; Cave, M.D.; Eisenach, K.D. Intracellular Macrophage Growth Rates and Cytokine Profiles of Mycobacterium tuberculosis
Strains with Different Transmission Dynamics. J. Infect. Dis. 2005, 191, 453–460. [CrossRef] [PubMed]
61. Mvubu, N.E.; Pillay, B.; McKinnon, L.R.; Pillay, M. Mycobacterium tuberculosis strains induce strain-specific cytokine and chemokine
response in pulmonary epithelial cells. Cytokine 2018, 104, 53–64. [CrossRef]
62. Mourik, B.C.; de Steenwinkel, J.E.M.; de Knegt, G.J.; Huizinga, R.; Verbon, A.; Ottenhoff, T.H.M.; van Soolingen, D.; Leenen, P.J.M.
Mycobacterium tuberculosis clinical isolates of the Beijing and East-African Indian lineage induce fundamentally different host
responses in mice compared to H37Rv. Sci. Rep. 2019, 9, 19922. [CrossRef]
63. Manca, C.; Reed, M.B.; Freeman, S.; Mathema, B.; Kreiswirth, B.; Barry, C.E.; Kaplan, G. Differential monocyte activation underlies
strain-specific Mycobacterium tuberculosis pathogenesis. Infect. Immun. 2004, 72, 5511–5514. [CrossRef]
64. Reed, M.B.; Domenech, P.; Manca, C.; Su, H.; Barczak, A.K.; Kreiswirth, B.N.; Kaplan, G.; Barry, C.E. A glycolipid of hypervirulent
tuberculosis strains that inhibits the innate immune response. Nature 2004, 431, 84–87. [CrossRef]
65. Tsenova, L.; Ellison, E.; Harbacheuski, R.; Moreira, A.L.; Kurepina, N.; Reed, M.B.; Mathema, B.; Barry, C.E.; Kaplan, G. Virulence
of selected Mycobacterium tuberculosis clinical isolates in the rabbit model of meningitis is dependent on phenolic glycolipid
produced by the bacilli. J. Infect. Dis. 2005, 192, 98–106. [CrossRef]
66. Theus, S.; Eisenach, K.; Fomukong, N.; Silver, R.F.; Cave, M.D. Beijing family Mycobacterium tuberculosis strains differ in their
intracellular growth in THP-1 macrophages. Int. J. Tuberc. Lung Dis. 2007, 11, 1087–1093.
67. Akbarzadeh, A.; Rezaei-Sadabady, R.; Davaran, S.; Joo, S.W.; Zarghami, N.; Hanifehpour, Y.; Samiei, M.; Kouhi, M.; Nejati-Koshki,
K. Liposome: Classification, preparation, and applications. Nanoscale Res. Lett. 2013, 8, 102. [CrossRef] [PubMed]
Int. J. Mol. Sci. 2021, 22, 1945 20 of 21
68. Sprott, G.D.; Dicaire, C.J.; Gurnani, K.; Sad, S.; Krishnan, L. Activation of Dendritic Cells by Liposomes Prepared from
Phosphatidylinositol Mannosides from Mycobacterium bovis Bacillus Calmette-Guerin and Adjuvant Activity In Vivo. Infect.
Immun. 2004, 72, 5235–5246. [CrossRef] [PubMed]
69. Rosenkrands, I.; Agger, E.M.; Olsen, A.W.; Korsholm, K.S.; Andersen, C.S.; Jensen, K.T.; Andersen, P. Cationic liposomes
containing mycobacterial lipids: A new powerful Th1 adjuvant system. Infect. Immun. 2005, 73, 5817–5826. [CrossRef]
70. Cardona, P.-J. RUTI: A new chance to shorten the treatment of latent tuberculosis infection. Tuberculosis 2006, 86, 273–289.
[CrossRef] [PubMed]
71. Homhuan, A.; Kogure, K.; Akaza, H.; Futaki, S.; Naka, T.; Fujita, Y.; Yano, I.; Harashima, H. New packaging method of
mycobacterial cell wall using octaarginine-modified liposomes: Enhanced uptake by and immunostimulatory activity of dendritic
cells. J. Control. Release 2007, 120, 60–69. [CrossRef]
72. Kawasaki, N.; Rillahan, C.D.; Cheng, T.-Y.; Van Rhijn, I.; Macauley, M.S.; Moody, D.B.; Paulson, J.C. Targeted Delivery of
Mycobacterial Antigens to Human Dendritic Cells via Siglec-7 Induces Robust T Cell Activation. J. Immunol. 2014, 193, 1560–1566.
[CrossRef] [PubMed]
73. Khademi, F.; Taheri, R.A.; Momtazi-Borojeni, A.A.; Farnoosh, G.; Johnston, T.P.; Sahebkar, A. Potential of Cationic Liposomes as
Adjuvants/Delivery Systems for Tuberculosis Subunit Vaccines. Rev. Physiol. Biochem. Pharmacol. 2018, 175, 47–69. [CrossRef]
74. Ioerger, T.R.; Feng, Y.; Ganesula, K.; Chen, X.; Dobos, K.M.; Fortune, S.; Jacobs, W.R.; Mizrahi, V.; Parish, T.; Rubin, E.; et al.
Variation among genome sequences of H37Rv strains of Mycobacterium tuberculosis from multiple laboratories. J. Bacteriol. 2010,
192, 3645–3653. [CrossRef]
75. Nakata, K.; Rom, W.N.; Honda, Y.; Condos, R.; Kanegasaki, S.; Cao, Y.; Weiden, M. Mycobacterium tuberculosis enhances human
immunodeficiency virus-1 replication in the lung. Am. J. Respir. Crit. Care Med. 1997, 155, 996–1003. [CrossRef]
76. Lawn, S.D.; Pisell, T.L.; Hirsch, C.S.; Wu, M.; Butera, S.T.; Toossi, Z. Anatomically compartmentalized human immunodeficiency
virus replication in HLA-DR+ cells and CD14+ macrophages at the site of pleural tuberculosis coinfection. J. Infect. Dis. 2001, 184,
1127–1133. [CrossRef]
77. McDonald, D.; Wu, L.; Bohks, S.M.; KewalRamani, V.N.; Unutmaz, D.; Hope, T.J. Recruitment of HIV and its receptors to dendritic
cell-T cell junctions. Science 2003, 300, 1295–1297. [CrossRef]
78. Wu, L. Biology of HIV mucosal transmission. Curr. Opin. HIV AIDS 2008, 3, 534–540. [CrossRef]
79. Miyake, Y.; Toyonaga, K.; Mori, D.; Kakuta, S.; Hoshino, Y.; Oyamada, A.; Yamada, H.; Ono, K.-I.; Suyama, M.; Iwakura, Y.; et al.
C-type lectin MCL is an FcRγ-coupled receptor that mediates the adjuvanticity of mycobacterial cord factor. Immunity 2013, 38,
1050–1062. [CrossRef]
80. Rousseau, C.; Turner, O.C.; Rush, E.; Bordat, Y.; Sirakova, T.D.; Kolattukudy, P.E.; Ritter, S.; Orme, I.M.; Gicquel, B.; Jackson, M.
Sulfolipid deficiency does not affect the virulence of Mycobacterium tuberculosis H37Rv in mice and guinea pigs. Infect. Immun.
2003, 71, 4684–4690. [CrossRef] [PubMed]
81. Kumar, P.; Schelle, M.W.; Jain, M.; Lin, F.L.; Petzold, C.J.; Leavell, M.D.; Leary, J.A.; Cox, J.S.; Bertozzi, C.R. PapA1 and PapA2 are
acyltransferases essential for the biosynthesis of the Mycobacterium tuberculosis virulence factor sulfolipid-1. Proc. Natl. Acad.
Sci. USA 2007, 104, 11221–11226. [CrossRef] [PubMed]
82. Granelli-Piperno, A.; Delgado, E.; Finkel, V.; Paxton, W.; Steinman, R.M. Immature dendritic cells selectively replicate
macrophagetropic (M-tropic) human immunodeficiency virus type 1, while mature cells efficiently transmit both M- and T-tropic
virus to T cells. J. Virol. 1998, 72, 2733–2737. [CrossRef]
83. Sanders, R.W.; de Jong, E.C.; Baldwin, C.E.; Schuitemaker, J.H.N.; Kapsenberg, M.L.; Berkhout, B. Differential transmission of
human immunodeficiency virus type 1 by distinct subsets of effector dendritic cells. J. Virol. 2002, 76, 7812–7821. [CrossRef]
84. Perot, B.P.; García-Paredes, V.; Luka, M.; Ménager, M.M. Dendritic Cell Maturation Regulates TSPAN7 Function in HIV-1 Transfer
to CD4+ T Lymphocytes. Front. Cell. Infect. Microbiol. 2020, 10, 70. [CrossRef] [PubMed]
85. Bafica, A.; Scanga, C.A.; Schito, M.L.; Hieny, S.; Sher, A. Cutting Edge: In Vivo Induction of Integrated HIV-1 Expression by
Mycobacteria Is Critically Dependent on Toll-Like Receptor 2. J. Immunol. 2003, 171, 1123–1127. [CrossRef]
86. Equils, O.; Schito, M.L.; Karahashi, H.; Madak, Z.; Yarali, A.; Michelsen, K.S.; Sher, A.; Arditi, M. Toll-Like Receptor 2 (TLR2)
and TLR9 Signaling Results in HIV-Long Terminal Repeat Trans-Activation and HIV Replication in HIV-1 Transgenic Mouse
Spleen Cells: Implications of Simultaneous Activation of TLRs on HIV Replication. J. Immunol. 2003, 170, 5159–5164. [CrossRef]
[PubMed]
87. Larson, E.C.; Novis, C.L.; Martins, L.J.; Macedo, A.B.; Kimball, K.E.; Bosque, A.; Planelles, V.; Barrows, L.R. Mycobacterium
tuberculosis reactivates latent HIV-1 in T cells in vitro. PLoS ONE 2017, 12, e0185162. [CrossRef] [PubMed]
88. Goletti, D.; Weissman, D.; Jackson, R.W.; Collins, F.; Kinter, A.; Fauci, A.S. The in vitro induction of human immunodeficiency
virus (HIV) replication in purified protein derivative-positive HIV-infected persons by recall antigen response to Mycobacterium
tuberculosis is the result of a balance of the effects of endogenous interleu. J. Infect. Dis. 1998, 177, 1332–1338. [CrossRef] [PubMed]
89. Hoshino, Y.; Tse, D.B.; Rochford, G.; Prabhakar, S.; Hoshino, S.; Chitkara, N.; Kuwabara, K.; Ching, E.; Raju, B.; Gold, J.A.;
et al. Mycobacterium tuberculosis-induced CXCR4 and chemokine expression leads to preferential X4 HIV-1 replication in human
macrophages. J. Immunol. 2004, 172, 6251–6258. [CrossRef] [PubMed]
90. Rodriguez, M.E.; Loyd, C.M.; Ding, X.; Karim, A.F.; McDonald, D.J.; Canaday, D.H.; Rojas, R.E. Mycobacterial phosphatidylinositol
mannoside 6 (PIM6) up-regulates TCR-triggered HIV-1 replication in CD4+ T cells. PLoS ONE 2013, 8, e80938. [CrossRef]
Int. J. Mol. Sci. 2021, 22, 1945 21 of 21
91. Tomlinson, G.S.; Bell, L.C.K.; Walker, N.F.; Tsang, J.; Brown, J.S.; Breen, R.; Lipman, M.; Katz, D.R.; Miller, R.F.; Chain, B.M.;
et al. HIV-1 infection of macrophages dysregulates innate immune responses to Mycobacterium tuberculosis by inhibition of
interleukin-10. J. Infect. Dis. 2014, 209, 1055–1065. [CrossRef]
92. Bhatt, K.; Gurcha, S.S.; Bhatt, A.; Besra, G.S.; Jacobs, W.R. Two polyketide-synthase-associated acyltransferases are required for
sulfolipid biosynthesis in Mycobacterium tuberculosis. Microbiology 2007, 153, 513–520. [CrossRef] [PubMed]
93. Dobson, G.; Minnikin, D.E.; Minnikin, S.M.; Parlett, J.H.; Goodfellow, M.; Ridell, M.; Magnusson, M. Systematic analysis of
complex mycobacterial lipids. In Chemical Methodscin Bacterial Systematics; Goodfellow, M., Minnikin, D.E., Eds.; Academic Press:
London, UK, 1985; Volume 1, pp. 237–265.
